Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) was the target of a significant growth in short interest in May. As of May 29th, there was short interest totaling 46,045 shares, a growth of 153.3% from the May 14th total of 18,181 shares. Currently, 1.8% of the shares of the stock are sold short. Based on an average daily volume of 130,709 shares, the days-to-cover ratio is currently 0.4 days.

Catheter Precision Price Performance

VTAK traded down $0.02 on Friday, reaching $1.05. The company had a trading volume of 23,079 shares, compared to its average volume of 100,020. The business has a 50 day simple moving average of $0.94 and a 200 day simple moving average of $1.52. The company has a market cap of $2.82 million, a price-to-earnings ratio of -0.08 and a beta of -1.01. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.06 and a current ratio of 0.06. Catheter Precision has a 52-week low of $0.75 and a 52-week high of $8.50.

Catheter Precision (NYSEAMERICAN:VTAK) last issued its quarterly earnings results on Monday, May 18th. The company reported ($1.39) EPS for the quarter, beating analysts’ consensus estimates of ($20.90) by $19.51. Catheter Precision had a negative net margin of 1,297.56% and a negative return on equity of 76.51%. The business had revenue of $0.43 million for the quarter, compared to analysts’ expectations of $1.60 million.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Catheter Precision stock. Millennium Management LLC bought a new position in Catheter Precision, Inc. (NYSEAMERICAN:VTAK) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned about 2.08% of Catheter Precision as of its most recent filing with the Securities & Exchange Commission. 20.34% of the stock is owned by hedge funds and other institutional investors.

About Catheter Precision

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.